Thanks for the explanation,KV.A's greed didn't help,lol,unless they can show that Makena is somehow safer than the local compound pharmacy stuff they are living on borrowed time with their debt load,if they could sell it to a larger more respected pharma they might survive.
By a more respected larger player,i mean someone the compound pharmacies would fear and someone FDA and insurance/medicaid would play ball with.
The meningitis debacle is going to harm all compounding pharmacies, even those with impeccable service. I wonder if the business model per se will be able to survive. From today’s NYT:
Market Data 
Markets 
AI
